October 14, 2021 — Cardiac computed tomography angiography (CTA) derived left atrium emptying fraction (LAEF) improves ...
Heart Valve Technology
This channel includes news and new device innovations about heart valve technologies, including the aortic valve, mitral valve, pulmonic valve, and tricuspid valve. This includes information on transcatheter valve technologies like transcatheter aortic valve replacement (TAVR, or implantation TAVI), transcatheter mitral valve repair or replacement (TMVR), transcatheter and surgical valve repairs, and surgical replacement valves. Newer devices are now being used for transcatheter tricuspid valve repair replacement (TTVR).
Tiberio Frisoli, M.D., interventional structural cardiologist, senior staff physician, Henry Ford Hospital, explains how ...
October 6, 2021 — Boston Scientific Corp. announced it entered into a definitive agreement to acquire Baylis Medical ...
![Two of the top technology headlines this past month was the FDA clearance of the Abbott Portico transcatheter aortic valve replacement (TAVR) device, and the first women to receive a Carmat artificial heart.](/sites/default/files/styles/content_feed_large/public/field/image/Portico%20and%20Carmat%20top%20content%20Sept%202021.jpg?itok=w3RU3h4_)
October 6, 2021 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...
Tom Jones, M.D., director, cardiac cath labs, Seattle Children’s Hospital, and principle investigator of the Medtronic ...
Dr. Neil Moat, MBBS, chief medical officer of Abbott's structural heart business, explains the latest advances in Abbott ...
![The U.S. Food and Drug Administration (FDA) has cleared the company's Portico with FlexNav transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery.](/sites/default/files/styles/content_feed_large/public/field/image/Abbott_Portico_TAVR_gradient_1200x628%20copy.jpg?itok=NNSa043J)
September 20, 2021 — Abbott announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Portico ...
September 13, 2021 — The European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery ...
September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart ...
July 15, 2021 — Vivasure Medical announced its development program for PerQseal Blue, a sutureless and fully ...
Doctor Andreas Ruck, interventional cardiologist and head of the mitral/tricuspid program, Karolinska University ...
![The Xeltis synthetic polymer restorative pulmonary valve is implanted surgically and acts as a scaffold for the patient's own cells to proliferate. The valve and conduit then bioresorbs over time, leaving behind a new valve made from the patient's own cells. The hope is this will reduce or eliminate the need for numerous repeat surgeries as a pediatric patient grows.](/sites/default/files/styles/content_feed_large/public/field/image/Xeltis_Pulmonary_Valve_ETR_A.jpg?itok=gIxmsurb)
July 8, 2021 – Xeltis announced it started the first pivotal trial for a synthetic polymer restorative pulmonary valve ...
June 29, 2021 – Cardiologists at Beaumont Health successfully replaced a 34-year-old woman’s tricuspid valve in a rare ...
It is brutal and very expensive to bring a new transcatheter valve to market. Boston Scientific invested vast amounts of ...
June 7, 2021 — Edwards Lifesciences recently announced that clinical results from the company's transcatheter mitral and ...